Astrana Health, Inc. (NASDAQ:ASTH) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 5.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 471,329 shares of the company’s stock after purchasing an additional 23,533 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.84% of Astrana Health worth $14,861,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Janus Henderson Group PLC acquired a new position in shares of Astrana Health during the 3rd quarter worth $1,164,000. Loomis Sayles & Co. L P acquired a new position in shares of Astrana Health during the 3rd quarter worth $30,251,000. Principal Financial Group Inc. acquired a new position in shares of Astrana Health during the 3rd quarter worth $13,383,000. Victory Capital Management Inc. acquired a new position in shares of Astrana Health during the 3rd quarter worth $2,596,000. Finally, Franklin Resources Inc. acquired a new position in shares of Astrana Health during the 3rd quarter worth $1,187,000. 52.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ASTH shares. Robert W. Baird lowered their price objective on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. Truist Financial lowered their price objective on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a research note on Tuesday. Macquarie raised shares of Astrana Health to a “hold” rating in a research note on Monday, December 16th. Bank of America lowered their price objective on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Finally, Stifel Nicolaus lowered their price objective on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Astrana Health has a consensus rating of “Moderate Buy” and an average price target of $56.17.

Astrana Health Price Performance

NASDAQ:ASTH opened at $30.82 on Friday. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of 23.71, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The company’s 50-day moving average is $33.95 and its two-hundred day moving average is $42.67. Astrana Health, Inc. has a 12-month low of $23.12 and a 12-month high of $63.20.

Astrana Health (NASDAQ:ASTH) last released its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The firm had revenue of $665.21 million during the quarter, compared to analysts’ expectations of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. Research analysts expect that Astrana Health, Inc. will post 1.15 EPS for the current year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.